Brachytherapy firm Cianna Medical is highlighting two new studies that show excellent longer-term outcomes with its Strut-Adjusted Volume Implant (SAVI) breast brachytherapy applicator.
Cianna said the studies indicate low recurrence rates, few toxicities, excellent cosmetic outcomes, and high rates of survival with the SAVI applicator. A third study demonstrated the applicator's ability to precisely deliver radiation while avoiding critical structures, Cianna said.
The data came from the SAVI Collaborative Research Group, which studies the long-term outcomes of women who received accelerated partial breast irradiation (APBI) with the SAVI applicator. The results were presented at the American Society for Radiation Oncology (ASTRO) meeting last month in Atlanta.
The first study examined 101 patients with a median follow-up of 4.5 years; the researchers found toxicity rates of less than 3%, local control of 2%, and overall and cause-specific actuarial survival rates of 100%. The second study included 576 patients with a median follow-up of three years, and it showed low toxicity and a local recurrence rate of less than 2.5%, with overall and cause-specific actuarial survival rates of 99.5%.
The final study analyzed radiation treatment plans for more than 1,000 patients and demonstrated the SAVI applicator's ability to accurately deliver radiation, Cianna said.
